Jefferies resumes coverage on Cabaletta Bio stock with Buy rating
PositiveFinancial Markets

Jefferies has resumed coverage on Cabaletta Bio, giving the stock a 'Buy' rating. This is significant as it reflects confidence in the company's potential for growth and success in the biotech sector, which could attract more investors and boost the stock's performance.
— Curated by the World Pulse Now AI Editorial System